Low-dose desmopressin effective for nocturia

Low-dose desmopressin effective for nocturia
Desmopressin orally disintegrating tablets are effective and well-tolerated for nocturia among women and men at doses of 25 and 50 µg per day, respectively, according to two studies published in the September issue of The Journal of Urology.

(HealthDay)—Desmopressin orally disintegrating tablets are effective and well-tolerated for nocturia among women and men at doses of 25 and 50 µg per day, respectively, according to two studies published in the September issue of The Journal of Urology.

Peter K. Sand, M.D., from the Northshore University HealthSystem in Evanston, Ill., and colleagues conducted a three-month randomized trial to compare 25 µg desmopressin once daily with in 261 women (aged 19 to 87 years) with nocturia (two or more nocturnal voids). The researchers found that desmopressin correlated with a significant reduction in the mean number of nocturnal voids and with increased odds of a 33 percent or greater response versus placebo during three months (odds ratio, 1.85). At three months, desmopressin correlated with significantly increased time to first nocturnal void by 49 minutes compared with placebo. Desmopressin was well-tolerated and linked to significant increases in health related and sleep quality versus placebo.

Jeffrey P. Weiss, M.D., from the SUNY Downstate College of Medicine in Brooklyn, N.Y., and colleagues conducted a three-month randomized trial comparing 50 and 75 µg desmopressin with placebo among 385 men (aged 20 to 87 years) with nocturia. The researchers found that desmopressin correlated with significantly reduced number of nocturnal voids and with increased odds of a 33 percent or greater response (odds ratios, 1.98 and 2.04 for 50 and 75 µg, respectively). The time to first void increased significantly by about 40 minutes from baseline with 50 and 75 µg desmopressin versus placebo.

"In summary, nocturia is a rather simple symptom that is rather complicated to manage. The etiology is often multifactorial and many patients defy categorization," writes the author of an accompanying editorial. "Desmopressin represents a unique but carries the potential for a severe complication (hyponatremia). Gender specific dosing appears to decrease this risk but monitoring serum sodium levels is still indicated."

Several authors from both studies disclosed financial ties to pharmaceutical companies, including Ferring, which supported the studies and manufactures desmopressin.

More information: Abstract - Sand
Full Text
Abstract - Weiss
Full Text
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Dexamethasone beats placebo for cancer-related fatigue

Aug 01, 2013

(HealthDay)—For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue (CRF), according to a study published online July 29 in the Journal of Clinical On ...

Recommended for you

Recorded Ebola deaths top 7,000

1 hour ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

5 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.